These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 24403265)

  • 21. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study.
    Reboul F; Brewer Y; Vincent P; Chauvet B; Faure CF; Taulelle M
    Int J Radiat Oncol Biol Phys; 1996 May; 35(2):343-50. PubMed ID: 8635942
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer.
    Carter DL; Garfield D; Hathorn J; Mundis R; Boehm KA; Ilegbodu D; Asmar L; Reynolds C
    Clin Lung Cancer; 2012 May; 13(3):205-13. PubMed ID: 22138037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.
    Curran WJ; Paulus R; Langer CJ; Komaki R; Lee JS; Hauser S; Movsas B; Wasserman T; Rosenthal SA; Gore E; Machtay M; Sause W; Cox JD
    J Natl Cancer Inst; 2011 Oct; 103(19):1452-60. PubMed ID: 21903745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study of protracted low dose cisplatin and etoposide with concurrent thoracic radiotherapy in unresectable stage III nonsmall cell lung cancer.
    Blanke C; DeVore R; Shyr Y; Epstein B; Murray M; Hande K; Stewart S; Johnson D
    Int J Radiat Oncol Biol Phys; 1997 Jan; 37(1):111-6. PubMed ID: 9054884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
    Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
    Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial.
    Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A
    Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
    Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
    BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Carboplatin/etoposide/radiation plus escalating doses of paclitaxel in stage III non-small cell lung cancer: a preliminary report.
    Bonomi P; Faber LP; Recine D; Lincoln S
    Semin Oncol; 1995 Aug; 22(4 Suppl 9):42-7. PubMed ID: 7644927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Carboplatin, S-1 and concurrent thoracic radiotherapy for elderly patients with locally advanced non-small cell lung cancer: a multicenter Phase I/II study.
    Niho S; Hosomi Y; Okamoto H; Nihei K; Tanaka H; Hida T; Umemura S; Goto K; Akimoto T; Ohe Y
    Jpn J Clin Oncol; 2019 Jul; 49(7):614-619. PubMed ID: 30916304
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology.
    Hanna N; Neubauer M; Yiannoutsos C; McGarry R; Arseneau J; Ansari R; Reynolds C; Govindan R; Melnyk A; Fisher W; Richards D; Bruetman D; Anderson T; Chowhan N; Nattam S; Mantravadi P; Johnson C; Breen T; White A; Einhorn L; ;
    J Clin Oncol; 2008 Dec; 26(35):5755-60. PubMed ID: 19001323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer.
    Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T
    Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Paclitaxel (Taxol) and carboplatin followed by concomitant paclitaxel, cisplatin and radiotherapy for inoperable stage III NSCLC.
    Isokangas OP; Joensuu H; Halme M; Jekunen A; Mattson K
    Lung Cancer; 1998 May; 20(2):127-33. PubMed ID: 9711531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): paclitaxel plus carboplatin versus vinorelbine plus cisplatin.
    Chang WJ; Sun JM; Lee JY; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2014 Apr; 84(1):51-5. PubMed ID: 24521819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel triplet regimen with paclitaxel, carboplatin and gemcitabine (PACCAGE) as induction chemotherapy for locally advanced unresectable non small cell lung cancer (NSCLC).
    Schallier D; Neyns B; Fontaine C; Steene JV; De Mey J; Meysman M; De Grève J
    Lung Cancer; 2007 May; 56(2):247-54. PubMed ID: 17337086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small-cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results.
    Semrau S; Bier A; Thierbach U; Virchow C; Ketterer P; Fietkau R
    Strahlenther Onkol; 2003 Dec; 179(12):823-31. PubMed ID: 14652671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
    Choy H; Akerley W; Safran H; Graziano S; Chung C; Williams T; Cole B; Kennedy T
    J Clin Oncol; 1998 Oct; 16(10):3316-22. PubMed ID: 9779707
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stage III Non-Small-Cell Lung Cancer Treated With Concurrent Chemoradiation Followed or Not by Consolidation Chemotherapy: A Survival Analysis From a Brazilian Multicentric Cohort.
    Cordeiro de Lima VC; Baldotto CS; Barrios CH; Sobrinho EM; Zukin M; Mathias C; Zaffaroni F; Nery RC; Madeira G; Amadio AV; Coelho JC; Geib G; Simões MF; Castro G
    J Glob Oncol; 2018 Sep; 4():1-11. PubMed ID: 30241276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
    Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
    Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Results of a phase II concurrent chemoradiotherapy study using three-dimensional conformal radiotherapy with cisplatin and oral etoposide in stage III nonsmall-cell lung cancer.
    Chen LM; Ignacio L; Jacobs R; Kozloff M; Telfer M; Elahi R; Evans R; Vijayakumar S
    Radiat Oncol Investig; 1999; 7(1):49-53. PubMed ID: 10030624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.